Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pexidartinib + RT + TMZ in Newly Diagnosed Glioblastoma
NCT01790503Phase 2Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jul 2013
- Primary completion
- Nov 2017
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of pexidartinib in glioblastoma (GBM), Gliosarcoma (GS), sponsored by Daiichi Sankyo Co., Ltd.. Started Jul 2013; status: completed.
02
Drugs
pexidartinib
03
Conditions
glioblastoma (GBM)Gliosarcoma (GS)
Beyond the preview
Go deeper on NCT01790503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01790503.